SynthesisFrontiers in medicine2025
Kidney injury molecule 1 in the early detection of acute kidney injury-a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Advancements in early biomarkers of acute kidney injury: from traditional indicators to a paradigm shift in lactate metabolism.Annals of medicine · 2026Review
- Multimodal biomarker approach using urinary prostaglandin E2, kidney injury molecule-1 and resistive index for assessing kidney adaptation in transplant recipients.BMC nephrology · 2026Article
- Article
- Multiparametric MRI as predictors for evaluating renal ischemia reperfusion injury and protective effect of Mito-TEMPO in rat model.BMC nephrology · 2026Article
- High-Dose Voclosporin Protects Against Acute Kidney Injury via Regnase-2-Mediated NGAL MRNA Decay.International journal of molecular sciences · 2026Article
- Hypertension-Induced Renal Injury: From Pathophysiology to Therapeutic Perspectives.Biomedicines · 2026Review
- Temporal dynamics of glomerular and microvascular remodeling in high-altitude renal injury: a structure-function analysis in rats.Frontiers in physiology · 2026Article
- Urinary KIM-1 for Early Detection of Acute Kidney Injury in Neonates: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney Injury Molecule 1 (KIM-1) is a biomarker of proximal tubular injury that can be used for the early detection of acute kidney injury (AKI). This study was designed to systematically review the relevant literature to assess the role of urinary KIM-1 (uKIM-1) and blood KIM-1 (bKIM-1) in diagnosing adult AKI. Methods: We searched PubMed, Embase, Cochrane, web of science for literature published until 7 August 2024, using the Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS-2). Sensitivity, specificity, and area under the curve (AUC) values from the included studies were combined using stata 18. Results: In total, 41 studies involving 1,790 patients were included. The estimated sensitivity of uKIM-1 for diagnosing adult AKI was 0.73 (95% CrI, 0.67-0.78), the specificity was 0.75 (95% CrI, 0.70-0.80), and the AUC was 0.81 (95% CrI 0.77-0.84); while the estimated sensitivity of bKIM-1 for diagnosing AKI was 0.72 (95% CrI 0.65-0.79), specificity was 0.79 (95% CrI, 0.70-0.86), and AUC was 0.81 (95% CrI 0.77-0.84). Conclusion: uKIM-1 and bKIM-1 show potential as biomarkers for predicting AKI in adult patients, demonstrating relatively high sensitivity and specificity. However, the current meta-analysis does not provide sufficient evidence to make definitive conclusions, and further studies and clinical trials are needed to determine the practical utility of uKIM-1 and bKIM-1 in clinical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.